NUFORMIX PLC

Pre-Annual General Meeting Information • Aug 1, 2022

National Storage Mechanism | Additional information

RNS Number : 4720U

Nuformix PLC

01 August 2022

1 August 2022

Nuformix plc

("Nuformix" or the "Company" or the "Group")

Posting of Annual Report and Notice of AGM

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual Financial Report for the year ended 31 March 2022 (the "Annual Financial Report 2022") and the 2022 Notice of Annual General Meeting ("AGM") are today being posted to its shareholders:

A full pdf version of the Annual Financial Report 2022 together with the Notice of Annual General Meeting is available for download from the Investor Information section on the Company's website www.nuformix.com.

The Annual Financial Report 2022 will be filed with the Registrar of Companies in due course and copies can be obtained from the Company Secretary, SGH Company Secretaries Limited, 60 Gracechurch Street, London, EC3V 0HR.

The Annual General Meeting will be held on 25 August 2022 at 2.00 pm at the offices of Shakespeare Martineau, 6th floor, 60 Gracechurch Street, London, EC3V 0HR.

Enquiries:

Nuformix plc
Dr Julian Gilbert, Non-executive Chairman	Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)	+44 (0) 20 3650 3650
John Howes (Corporate Broking)	+44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe Zach Cohen	+44 (0) 20 3934 6630 nuformix@investor-focus.co.uk

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAFLFLLTLILIIF